IL277495B2 - Modulators of protein-coupled receptors - G - Google Patents

Modulators of protein-coupled receptors - G

Info

Publication number
IL277495B2
IL277495B2 IL277495A IL27749520A IL277495B2 IL 277495 B2 IL277495 B2 IL 277495B2 IL 277495 A IL277495 A IL 277495A IL 27749520 A IL27749520 A IL 27749520A IL 277495 B2 IL277495 B2 IL 277495B2
Authority
IL
Israel
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
independently selected
group
Prior art date
Application number
IL277495A
Other languages
English (en)
Hebrew (he)
Other versions
IL277495A (en
IL277495B1 (en
Original Assignee
Carmot Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carmot Therapeutics Inc filed Critical Carmot Therapeutics Inc
Publication of IL277495A publication Critical patent/IL277495A/en
Publication of IL277495B1 publication Critical patent/IL277495B1/en
Publication of IL277495B2 publication Critical patent/IL277495B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL277495A 2018-03-23 2019-03-22 Modulators of protein-coupled receptors - G IL277495B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862647604P 2018-03-23 2018-03-23
PCT/US2019/023726 WO2019183577A1 (en) 2018-03-23 2019-03-22 Modulators of g-protein coupled receptors

Publications (3)

Publication Number Publication Date
IL277495A IL277495A (en) 2020-11-30
IL277495B1 IL277495B1 (en) 2024-04-01
IL277495B2 true IL277495B2 (en) 2024-08-01

Family

ID=67986596

Family Applications (3)

Application Number Title Priority Date Filing Date
IL277495A IL277495B2 (en) 2018-03-23 2019-03-22 Modulators of protein-coupled receptors - G
IL311177A IL311177B2 (en) 2018-03-23 2019-03-22 G-protein-coupled receptor modulators
IL323264A IL323264A (en) 2018-03-23 2025-09-09 G-protein-coupled receptor modulators

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL311177A IL311177B2 (en) 2018-03-23 2019-03-22 G-protein-coupled receptor modulators
IL323264A IL323264A (en) 2018-03-23 2025-09-09 G-protein-coupled receptor modulators

Country Status (18)

Country Link
US (3) US11535660B1 (cg-RX-API-DMAC10.html)
EP (1) EP3768294A4 (cg-RX-API-DMAC10.html)
JP (2) JP7526716B2 (cg-RX-API-DMAC10.html)
KR (2) KR102960848B1 (cg-RX-API-DMAC10.html)
CN (1) CN112236161A (cg-RX-API-DMAC10.html)
AR (1) AR115016A1 (cg-RX-API-DMAC10.html)
AU (2) AU2019237507B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020019148A2 (cg-RX-API-DMAC10.html)
CA (1) CA3094820A1 (cg-RX-API-DMAC10.html)
EA (1) EA202092269A1 (cg-RX-API-DMAC10.html)
IL (3) IL277495B2 (cg-RX-API-DMAC10.html)
MX (2) MX2020009950A (cg-RX-API-DMAC10.html)
MY (1) MY205468A (cg-RX-API-DMAC10.html)
PH (1) PH12020551539A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202009338SA (cg-RX-API-DMAC10.html)
TW (2) TW202444405A (cg-RX-API-DMAC10.html)
UA (1) UA129084C2 (cg-RX-API-DMAC10.html)
WO (1) WO2019183577A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020009950A (es) * 2018-03-23 2021-04-28 Carmot Therapeutics Inc Moduladores de receptores acoplados a proteina g.
JP7688891B2 (ja) * 2021-01-18 2025-06-05 国立大学法人東海国立大学機構 ペプチド
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
KR20240007251A (ko) * 2021-05-13 2024-01-16 카모트 테라퓨틱스, 인크. G-단백질 결합 수용체의 조절제
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
KR102703958B1 (ko) 2021-11-01 2024-09-09 국민대학교 산학협력단 글루카곤 유사 펩타이드-1 수용체의 양성 알로스테릭 조절제의 스크리닝 방법 및 그 방법에 따라 스크리닝된 글루카곤 유사 펩타이드-1 수용체의 양성 알로스테릭 조절제
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024089216A1 (en) 2022-10-27 2024-05-02 Syngenta Crop Protection Ag Novel sulfur-containing heteroaryl carboxamide compounds
US12473382B2 (en) 2022-11-04 2025-11-18 Lg Chem, Ltd. Hologram recording medium and optical element comprising the same
US20250298372A1 (en) * 2022-11-04 2025-09-25 Lg Chem, Ltd. Hologram recording medium and optical element comprising the same
KR20240064272A (ko) * 2022-11-04 2024-05-13 주식회사 엘지화학 불소계 화합물, 광중합성 조성물, 홀로그램 기록 매체, 이의 제조 방법 및 이를 포함하는 광학 소자
JP2026500298A (ja) 2022-12-15 2026-01-06 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物剤として有用である新規な二環式カルボキサミド化合物
WO2024217497A1 (en) * 2023-04-21 2024-10-24 The University Of Hong Kong Novel small molecule agonists of insulin receptor (insr) as anti-diabetes drugs
IL325257A (en) * 2023-06-22 2026-02-01 Carmot Therapeutics Inc Synthesis of GLP-1R/GIPR agonists and their starting materials
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
TW202615099A (zh) * 2024-07-31 2026-04-16 美商卡默療法股份有限公司 Glp—1r/gipr促效劑之合成
TW202620036A (zh) 2024-09-27 2026-05-16 美商卡默療法股份有限公司 肽酪胺酸-酪胺酸(pyy)類似物及glp-1r促效劑之組合療法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO2000034331A2 (en) * 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
WO2004067548A2 (en) * 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1883419A2 (en) * 2005-05-06 2008-02-06 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2011094337A1 (en) * 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
GB2551945A (en) * 2015-12-18 2018-01-10 Heptares Therapeutics Ltd Novel GLP-1 receptor agonist peptides

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
CN1364167A (zh) 1999-02-26 2002-08-14 阿瑞那制药公司 G蛋白偶联受体6的小分子调节剂
EP1235618A2 (en) 1999-09-07 2002-09-04 Conjuchem, Inc. Bioconjugation in vivo to pulmonary or blood components
EP1302462A4 (en) 2000-07-17 2007-07-18 Takeda Pharmaceutical SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF
BR0315815A (pt) 2002-11-01 2005-09-13 Takeda Pharmaceutical Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
WO2005058823A1 (ja) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited ウレア誘導体、その製造法及び用途
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
WO2005087710A1 (ja) 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8957070B2 (en) 2005-04-20 2015-02-17 Takeda Pharmaceutical Company Limited Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
JP4094660B1 (ja) 2005-08-10 2008-06-04 武田薬品工業株式会社 糖尿病治療剤
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
CN101420941A (zh) * 2006-04-11 2009-04-29 艾尼纳制药公司 Gpr119受体激动剂用于增加骨质量和用于治疗骨质疏松症的用途,和其相关组合疗法
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
JP5399244B2 (ja) 2006-08-17 2014-01-29 アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
CN101573357B (zh) 2006-10-19 2013-01-23 武田药品工业株式会社 吲哚化合物
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
AU2008215490A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of PPAR-gamma
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素5員複素環化合物
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
ES2558842T3 (es) 2008-06-17 2016-02-09 Indiana University Research And Technology Corporation Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
US20120148586A1 (en) 2009-08-27 2012-06-14 Joyce Ching Tsu Chou Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders
US8426414B2 (en) 2009-10-09 2013-04-23 Bristol-Myers Squibb Company Modulators of G protein-coupled receptor 88
US20120021979A1 (en) 2010-06-24 2012-01-26 Vanderbilt University GLP-1 receptor modulation of addiction, neuropsychiatric disorders and erectile dysfunction
US20150087586A1 (en) 2012-03-29 2015-03-26 Cebix, Inc. Pegylated c-peptide
CN104884056A (zh) * 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
JP6548579B2 (ja) 2012-12-06 2019-07-24 ヴィクトリア リンク リミテッド コンジュゲート化合物
US9766239B2 (en) 2013-03-13 2017-09-19 Arizona Board Of Regents On Behalf Of Arizona State University Synbodies for detection of human norovirus
CN105555756B (zh) 2013-06-28 2018-12-07 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
WO2015031268A1 (en) 2013-08-26 2015-03-05 Arizona Board Of Regents On Behalf Of Arizona State University High affinity synbodies for influenza
EP3218414A1 (en) * 2014-11-14 2017-09-20 Angiochem Inc. Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin
WO2016131893A1 (en) 2015-02-18 2016-08-25 Medimmune Limited Incretin fusion polypeptides
CN105219802A (zh) * 2015-10-10 2016-01-06 广西大学 胰岛组织特异性表达GIPRdn慢病毒载体及其应用
MX2020009950A (es) * 2018-03-23 2021-04-28 Carmot Therapeutics Inc Moduladores de receptores acoplados a proteina g.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043707A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO2000034331A2 (en) * 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues of glp-1
WO2004067548A2 (en) * 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
EP1883419A2 (en) * 2005-05-06 2008-02-06 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
WO2011094337A1 (en) * 2010-01-27 2011-08-04 Indiana University Research And Technology Corporation Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity
GB2551945A (en) * 2015-12-18 2018-01-10 Heptares Therapeutics Ltd Novel GLP-1 receptor agonist peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
B. FINAN ET AL,, UNIMOLECULAR DUAL INCRETINS MAXIMIZE METABOLIC BENEFITS IN RODENTS, MONKEYS, AND HUMANS, 30 October 2013 (2013-10-30) *
BONNET C?LIA S. ET AL,, STRUCTURAL STUDIES IN AQUEOUS SOLUTION OF NEW BINUCLEAR LANTHANIDE LUMINESCENT PEPTIDE CONJUGATES, 12 September 2008 (2008-09-12) *

Also Published As

Publication number Publication date
IL311177B2 (en) 2026-02-01
JP7526716B2 (ja) 2024-08-01
MX2020009950A (es) 2021-04-28
TW202444405A (zh) 2024-11-16
US20230357347A1 (en) 2023-11-09
EP3768294A1 (en) 2021-01-27
KR102960848B1 (ko) 2026-05-06
UA129084C2 (uk) 2025-01-08
JP2024156720A (ja) 2024-11-06
TW202012432A (zh) 2020-04-01
US11535660B1 (en) 2022-12-27
AR115016A1 (es) 2020-11-18
CN112236161A (zh) 2021-01-15
IL311177A (en) 2024-04-01
WO2019183577A1 (en) 2019-09-26
IL277495A (en) 2020-11-30
US20260176320A1 (en) 2026-06-25
AU2019237507A1 (en) 2020-10-08
JP2021531259A (ja) 2021-11-18
AU2025202679A1 (en) 2025-05-22
KR20260069782A (ko) 2026-05-15
AU2019237507B2 (en) 2025-04-03
IL323264A (en) 2025-11-01
IL277495B1 (en) 2024-04-01
PH12020551539A1 (en) 2021-06-07
BR112020019148A2 (pt) 2021-01-26
SG11202009338SA (en) 2020-10-29
TWI840348B (zh) 2024-05-01
EP3768294A4 (en) 2022-05-04
IL311177B1 (en) 2025-10-01
KR20210008834A (ko) 2021-01-25
MX2025006799A (es) 2025-07-01
CA3094820A1 (en) 2019-09-26
EA202092269A1 (ru) 2020-12-14
MY205468A (en) 2024-10-22

Similar Documents

Publication Publication Date Title
IL277495B1 (en) Modulators of g-protein coupled receptors
JP2024156720A5 (cg-RX-API-DMAC10.html)
JP2024517942A5 (cg-RX-API-DMAC10.html)
US6204288B1 (en) 1,2-dithiolane derivatives
HK1258817A1 (zh) 合成三萜类化合物及用以治病之方法
RU2399613C2 (ru) Ингибиторы цистеиновой протеазы катепсина
JP2023540609A5 (cg-RX-API-DMAC10.html)
US20120065260A1 (en) Novel compounds
AU2020358970B2 (en) Chinone-, hydrochinome- and naphthochinone-analogues of vatiquione for treatment of mitochondrial disorder diseases
AR065657A1 (es) DERIVADOS DE 4-OXO-TIAZOL, COMPOSICIoN FARMACÉUTICA, MÉTODO DE PREPARACIoN DE LA MISMA Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MODULADAS POR EL RECEPTOR ALFA RELACIONADOS CON ESTRoGENOS.
JP2019534248A (ja) アミリン類似体
US20180280480A1 (en) Compositions and peptides having dual glp-1r and glp-2r agonist activity
JP6698643B2 (ja) 多発性硬化症の治療のための組成物及び方法
WO2015135474A1 (zh) 一类五环三萜类化合物及其在制备治疗阿尔兹海默病的药物中的用途
JP2021512112A (ja) グレリンo−アシルトランスフェラーゼ(goat)阻害薬として使用するためのヘテロシクリル置換オキサジアゾロピリジン誘導体
JP2015516419A (ja) Sglt1阻害剤としてのピラゾール化合物
Tradtrantip et al. Aquaporin water channels in transepithelial fluid transport
US6127394A (en) 1,2-Dithiolane derivatives
WO2016046680A2 (en) Compositions and methods for the treatment of liver metabolic diseases
ES2236742T3 (es) Uso de compuestos de la 19-nor-vitamina d para la prevencion de la.
KR20240170837A (ko) 당뇨병 및 비만 및 관련 질환의 치료 및/또는 예방을 위한 약물의 제조에서의 폴리펩티드의 약학적 용도
JP2015518854A (ja) 多発性硬化症の治療のための組成物および方法
US10358405B2 (en) Myricanol derivatives and uses thereof for treatment of neurodegenerative diseases
JP4076441B2 (ja) 新規脂肪族化合物、その製造方法、及びその利用方法
KR20260066098A (ko) 인간 질환 및 장애 치료를 위한 안정적인 glp-1 유사체